12-4-17/OCBJ: “Peregrine Full Speed Ahead In Shift To CDMO - Board To Add Mfg. Experience” By: Sherry Hsieh “Less than 6 months since investors issued a public statement calling for Peregrine Pharmaceuticals Inc. to cease clinical dev. activities of its cancer drug and focus on growing its biologics manufacturing business, the company is well on its way to completing the transition...” (must subscribe) http://www.ocbj.com/news/2017/dec/04/peregrine-full-speed-ahead-shift-cdmo/
If anybody subscribes to this, maybe they could share a paraphrase or a couple of quotes.